Topical brimonidine tartrate gel 0.5%: a new therapy for facial erythema in the context of rosacea.

By Dra. Florez

 

Dr. Joseph Fowler Jr. and co-workers have just published a very interesting paper in the British Journal of Dermatology:

Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter randomized and vehicle-controlled studies.

Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M; on behalf of the Brimonidine Phase II study group.

Br J Dermatol. 2011 Nov 2. PMID: 22050040

The authors present the background of the clinical problem underlining in their article that rosacea is a very common disorder in the dermatological setting. Moreover, due to its tendency to recur involving the central facial area and coexisting with frequent flushing episodes, rosacea can become a skin condition with important emotional impact.  Inflammatory lesions of rosacea, such as papules and pustules, can be managed with systemic tetracyclines, azelaic acid or metronidazole.  Unfortunately, there is currently no approved drug for the treatment of facial erythema in the context of rosacea, although it is a feature that is present in nearly all the patients. Erythema in patients suffering from rosacea is thought to be caused by a malfunction in the cutaneous vasomotor system, resulting in pathological vasodilatation. Brimonidine tartrate (BT) is a highly selective alfa2-adrenergic receptor agonist, and therefore a potent vasoconstrictive agent.

The authors communicate two Phase II studies focusing on the efficacy and safety of BT in the treatment of moderate to severe erythema of rosacea, as well as to determine its optimal dose regimen.

The authors conclude that:

  1. BT gel 0.5 % applied once a day significantly reduces erythema compared to the vehicle gel.
  2. Treatment is well tolerated. Patients must be instructed to avoid eye contact in order to prevent from intra-ocular pressure decrease.
  3. No tachyphylaxis or worsening of inflammatory lesions is observed.

 

In conclusion, this is an original article reporting promising results for a frequent and challenging condition.

 
  • 8 Comments in “Topical brimonidine tartrate gel 0.5%: a new therapy for facial erythema in the context of rosacea.”
  1. james walker says:  

    can public now buy brimonidine tartrate gel 0.5%? From james walker

  2. Dra. Florez says:  

    Dear James,
    To my Knowledge, brimonidine tartrate is being used in ophtalmic solutions to treat glaucoma, but topical brimonidine tartrate gel is not currently available for the public. If you are interested in this subject you may contact Galderma to find out more information.
    Sincerely,
    Ángeles Flórez.

  3. Glenn Davidson says:  

    Hello,

    Long sufferer of facial redness/flushing,so I would be very interested on the topical drug Brimonidine tartrate gel.

    I understand in order to achieve more information of the topical drug I need to contact Galderma.
    I would be forever greateful if you can give ne the correct contact information i.e email address in order to discuss the above drug in detail,

    Thanks for any info/reply,
    Mr Glenn Davidson,UK

  4. Dra. Florez says:  

    You may contact them in http://www.galderma.es. However, the product is still under development.
    Yours sincerely,
    Dr. A. Flórez.

  5. Ami Lavie says:  

    dear dr florez

    Is the gel Available ?

    thanks

    Ami

  6. Dra. Florez says:  

    Unfortunately the gel is not on the market yet.
    Sincerely,
    Dr. Flórez.

  7. remigio plaitano says:  

    could you explain the exact way to prepare in galenic formulation; it is the one you used in the study. isn’t it?

  8. Dra. Florez says:  

    You can consult the exact way Dr. Fowler and coworkers do the formulation in the article in press:

    Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter randomized and vehicle-controlled studies.

    Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M; on behalf of the Brimonidine Phase II study group.

    Br J Dermatol. 2011 Nov 2. PMID: 22050040

    Yours sincerely,

    Dr. A. Flórez

 

Leave a Reply

If you would like to add an image or a PDF file to detail your comment, you can upload it here.
JPG file (less than 500 pixels wide) or PDF file